253 92 34MB
English Pages 444 Year 2020
Jenny Stanford Series on Biocatalysis Volume 7
Pharmaceutical Biocatalysis
Jenny Stanford Series on Biocatalysis
Series Editor
Peter Grunwald
Titles in the Series Published Vol. 1 Industrial Biocatalysis Peter Grunwald, ed.
2015
978-981-4463-88-1 (Hardcover)
978-981-4463-89-8 (eBook)
Vol. 2 Handbook of CarbohydrateModifying Biocatalysts Peter Grunwald, ed.
2016
978-981-4669-78-8 (Hardcover)
978-981-4669-79-5 (eBook)
Vol. 3 Biocatalysis and Nanotechnology Peter Grunwald, ed.
2017
978-981-4613-69-9 (Hardcover)
978-1-315-19660-2 (eBook)
Vol. 4 Pharmaceutical Biocatalysis: Fundamentals, Enzyme Inhibitors, and Enzymes in Health and Diseases Peter Grunwald, ed.
2019
978-981-4800-61-7 (Hardcover)
978-0-429-29503-4 (eBook)
Vol. 5 Pharmaceutical Biocatalysis: Chemoenzymatic Synthesis of Active Pharmaceutical Ingredients Peter Grunwald, ed.
2019
978-981-4800-80-8 (Hardcover)
978-0-429-35311-6 (eBook)
Vol. 6 Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies Peter Grunwald, ed.
2021
978-981-4877-13-8 (Hardcover)
978-1-003-04539-7 (eBook)
Vol. 7 Pharmaceutical Biocatalysis: Drugs, Genetic Diseases, and Epigenetics Peter Grunwald, ed.
2021
978-981-4877-14-5 (Hardcover)
978-1-003-04541-0 (eBook)
Forthcoming
Vol. 8 Agricultural Biocatalysis Peter Grunwald, ed. 2022 Vol. 9 Biocatalysis for Sustainable Process Development Peter Grunwald, ed. 2023
Jenny Stanford Series on Biocatalysis Volume 7
Pharmaceutical Biocatalysis Drugs, Genetic Diseases, and Epigenetics
edited by
Peter Grunwald
Published by Jenny Stanford Publishing Pte. Ltd. Level 34, Centennial Tower 3 Temasek Avenue Singapore 039190 Email: [email protected] Web: www.jennystanford.com
British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library. Pharmaceutical Biocatalysis: Drugs, Genetic Diseases, and Epigenetics Copyright © 2021 Jenny Stanford Publishing Pte. Ltd. All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.
For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.
Cover: Yew needles and berry, by Dr. Gorden Cragg. National Cancer Institute, USA. ISBN 978-981-4877-14-5 (Hardcover) ISBN 978-1-003-04541-0 (eBook)
Contents Preface
1. Fermentative Production of Vitamin B6
xv
1
Jonathan Rosenberg, Björn Richts, and Fabian M. Commichau
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
Introduction De novo Synthesis of Vitamin B6 Control of Vitamin B6 Homeostasis Engineering Microorganisms for the Production
of B6 Vitamers Novel Routes for Vitamin B6 Biosynthesis and
Production Rational Design and Construction of a Vitamin
B6-Producing Bacterium Alternative Approaches for Enhancing Vitamin
B6 Production Conclusions
2. Exploring Alternative Taxol Sources: Biocatalysis of
7-b-Xylosyl-10-Deacetyltaxol and Application for Taxol
Production
1
4
7
10
17
20
23
25
35
Wan-Cang Liu, Bing-Juan Li, Ting Gong, and Ping Zhu
2.1 Introduction 2.2 High-Cell-Density Fermentation of the
Engineered Yeast 2.2.1 General Fed-Batch HCDF Process 2.2.2 HCDF Process Optimization 2.2.2.1 Elimination of pure oxygen
supplement by increasing air
pressure 2.2.2.2 Fermentation using biomass-stat
strategy
35
37
38
38
38
39
vi
Contents
2.2.2.3 Fermentation using reduced
induction DO value 2.2.2.4 Optimization of initial induction
biomass 2.2.3 Scaling Up HCDF from Pilot Scale to
Demonstration/Commercial Scale 2.3 Biocatalysis of 7-b-Xylosyltaxanes 2.3.1 General Biocatalysis Protocol 2.3.2 Optimization of the Biocatalysis 2.3.2.1 Impact of dry cell amount on
biocatalysis 2.3.2.2 Impact of DMSO concentration on
biocatalysis 2.3.2.3 Impact of substrate concentration
on product yield 2.3.2.4 Effect of antifoam supplement on
biocatalysis 2.3.3 Scale-Up Biocatalysis 2.4 One-Pot Enzymatic Reaction from 7-b-Xylosyl-
10-Deacetyltaxol to Taxol 2.4.1 Reaction System for the Biocatalysis 2.4.2 Protein Engineering of the
10-b-Acetyltransferase 2.4.2.1 l-Alanine scanning mutagenesis 2.4.2.2 Saturation mutagenesis 2.4.2.3 Construction of one-pot reaction
system 2.5 Summary
3. Molecular Farming through Plant Engineering: A
Cost-Effective Approach for Producing Therapeutic
and Prophylactic Proteins
40
41
41
44
45
45
45
45
46
46
47
49
49
50
50
51
53
53
57
Prakash Narayana Reddy, Krupanidhi Srirama,
and Vijaya R. Dirisala
3.1 Introduction 3.2 Strategies for Production of Therapeutics in Plants 3.2.1 Stable Expression
57
59
59
Contents
3.2.2 Transient Expression 3.3 Plant-Made Vaccines 3.4 Plantibodies 3.5 Conclusions
4. Microbial Biotransformations in the Production and Degradation of Fluorinated Pharmaceuticals
61
62
68
74
81
Cormac D. Murphy and Aoife Phelan
4.1 Introduction 4.2 Fluorinated Natural Products 4.3 Production of Fluorinated Antibiotics in
Microorganisms 4.4 Biological Production of [18F]-Labelled
Compounds for PET Analysis 4.5 Microorganisms that Enable Fluorinated Drug
Design 4.6 Production of Fluorinated Drug Metabolites in
Microorganisms 4.7 Microbial Degradation of Fluorinated Drugs 4.8 Future Prospects and Challenges
5. Successful Screening of Potent Microorganisms
Producing l-Asparaginase
81
82
84
89
91
94
95
99
105
Archana Vimal and Awanish Kumar
5.1 Introduction 5.2 Purpose of Screening Prospective Source of
l-Asparaginase 5.2.1 High Cost of Treatment 5.2.2 Minimizing Side Effects 5.2.3 Prolongation of Half-Life 5.2.4 Explore the Multifaceted Use of
l-Asparaginase 5.3 Different Methods of Screening Potential Source
of l-Asparaginase 5.3.1 In silico Approach 5.3.2 Dye-Based Method
105
106
107
108
108
109
110
110
111
vii
viii
Contents
5.4 5.5
5.6
5.7
5.3.3 Assay-Based Method 5.3.3.1 Radioactive isotope assays 5.3.3.2 Indophenol assay 5.3.3.3 Coupled assay 5.3.3.4 Aspartic acid determination
assay 5.3.3.5 Hydroxylamine assay 5.3.3.6 Fluorometric assay 5.3.3.7 Direct nesslerization assay Activators and Inhibitors of l-Asparaginase Various Microbial Sources of l-Asparaginase 5.5.1 Microbial Sources 5.5.1.1 Bacterial source 5.5.1.2 Fungal source 5.5.2 Plant Source 5.5.3 Animal and Other Sources Pharmaceutical Application of l-Asparaginase 5.6.1 Chemotherapy 5.6.2 Infectious Disease 5.6.3 Autoimmune Disorder 5.6.4 Veterinary 5.6.5 Food Additive 5.6.6 Medical/Food Biosensor Conclusion
6. Biotransformation of Xenobiotics in Living
Systems—Metabolism of Drugs: Partnership of Liver
and Gut Microflora
113
114
114
114
114
115
115
115
116
117
117
120
120
120
121
121
121
122
123
123
123
124
124
129
Maja Đanić and Momir Mikov
6.1 6.2
Introduction Liver Metabolism 6.2.1 Phase I Biotransformation 6.2.1.1 Oxidations 6.2.1.2 Reductions 6.2.1.3 Hydrolysis
129
132
132
133
141
143
Contents
6.2.2 Phase II Biotransformation 6.2.2.1 Uridine diphosphate glucuronosyltransferases 6.2.2.2 Glutathione S-transferases 6.2.2.3 Methyltransferases 6.2.2.4 N-Acetyltransferases 6.2.2.5 Sulfotransferases 6.3 Metabolism of Xenobiotics in Gut 6.3.1 Luminal and Cell Wall Metabolism of
Drugs 6.3.2 Gut Microflora Implication in Xenobiotic
Metabolism 6.3.2.1 Reduction of drugs by microbiota 6.3.2.2 Microbial metabolism of drugs
by hydrolysis 6.4 Conclusion
7. Degradation of Pharmaceutically Active Compounds
by White-Rot Fungi and Their Ligninolytic Enzymes
144
147
148
149
150
151
152
153
153
156
159
160
167
Muhammad B. Asif and Faisal I. Hai
7.1 Introduction
7.2 PhAC Removal by WRF and Their Ligninolytic
Enzymes 7.2.1 Effect of Fungal Species 7.2.2 Effect of Enzyme Types
7.2.3 Effect of PhAC Properties on Their
Removal
7.2.3.1 Removal of PhACs containing
EDGs 7.2.3.2 Removal of PhACs containing
EWGs 7.2.3.3 Removal of PhACs containing
both EDGs and EWGs 7.2.3.4 Effect of hydrophobicity
7.2.4 Laccase-Redox Mediator System
167
170
171
180
188
190
191
191
192
193
ix
x
Contents
7.3 Impact of Physicochemical Characteristics of
Wastewater 7.4 Treatment of Real Wastewater by WRF and
Ligninolytic Enzymes 7.5 Future Research 7.6 Conclusion
8. Removal of Pharmaceutical Pollutants from
Municipal Sewage Mediated by Laccases
194
197
199
200
209
Thomas Hahn, Fabian Haitz, Jan Gajewski, Marius Mohr,
Marc Beckett, and Susanne Zibek
8.1 Introduction 8.2 Political and Societal Framework Conditions 8.2.1 Situation in Germany 8.2.2 Situation in Switzerland 8.3 Elimination of Pharmaceuticals with Physical
and Chemical Methods 8.3.1 Use of Activated Carbon 8.3.1.1 Granulated activated carbon 8.3.1.2 Powdered activated carbon 8.3.2 Use of Ozonation 8.3.3 Combined and Other Treatment Processes 8.3.3.1 Combined ozonation and activated
carbon 8.3.3.2 Combined ozone and hydrogen
peroxide 8.3.3.3 UV light 8.3.3.4 Membrane filtration 8.4 Theoretical Background and Application of
Laccases 8.4.1 Occurrence, Structure and Functionality
of Laccases 8.4.1.1 Origin and characterization 8.4.1.2 Reaction mechanism and
stoichiometry 8.4.1.3 Substrates and products
209
211
212
213
214
215
215
216
218
220
220
220
221
221
222
222
222
224
225
Contents
8.5 8.6 8.7 8.8
8.4.1.4 Inhibition of laccase activity 8.4.1.5 Immobilization types for laccases 8.4.2 Laccase-Mediator-System 8.4.3 Industrial Use of Laccase Elimination of Pharmaceuticals by the Use of
Laccase Comparison of Different Technologies for the
Elimination of Pharmaceuticals Assessing the Use of Laccase in Municipal
Wastewater Treatment 8.7.1 Use of Native Laccases 8.7.2 Use of Immobilized Laccase Summary and Conclusions towards Removal of
Pharmaceuticals
9. Mechanism of Drug Resistance in Staphylococcus
aureus and Future Drug Discovery
226
227
228
231
233
239
243
243
245
248
259
Felipe Wakasuqui, Ana Leticia Gori Lusa, Sven Falke,
Christian Betzel, and Carsten Wrenger
9.1 9.2 9.3 9.4
Introduction Drugs, Targets and Resistance Mechanism Future Drug Discovery and New Drugs Conclusion
10. Genome Editing and Gene Therapies: Complex and
Expensive Drugs
259
261
266
273
281
Peter Grunwald
10.1 Introduction 10.2 Some General Aspects 10.3 Genome Editing Techniques: Fundamentals 10.3.1 Zinc Finger Nucleases 10.3.2 TALENs 10.3.3 CRISPR/Cas Systems 10.3.3.1 Other applications of
CRISPR-systems 10.4 Therapeutic Genome Editing
281
282
284
286
288
289
293
296
xi
xii
Contents
10.4.1 HDR-Mediated Genome Editing 10.4.2 Ex vivo and in vivo Somatic Genome
Editing 10.4.3 Delivery Strategies 10.4.3.1 Adeno-associated viral vectors 10.4.3.2 Lentiviral vectors 10.4.3.3 Nanocarrier-based gene/drug
delivery 10.4.3.4 Physical methods 10.4.4 Genome Editing and Disease Models 10.4.5 Induced Pluripotent Stem Cells 10.4.5.1 Human diseases: From 2D to
3D iPSC models 10.4.5.2 Genome editing and human
iPSCs 10.4.6 Genome Editing and Diseases 10.4.6.1 Genome editing studies in
non-clinical development and
clinical trials 10.4.6.2 Examples of non-clinical
developments 10.4.6.3 CAR-T cell therapy and CRISPR 10.4.7 Gene Therapies without Modifying the
Existing DNA 10.4.8 Genome Editing-Based Therapeutics in
Clinical Trials and Off-Target Effects 10.4.8.1 Off-target effects 10.4.9 Genome Editing: Commercialization 10.4.10 Ethical Concerns and Regulatory Aspects 10.5 Summary and Outlook
11. Epigenetic and Metabolic Alterations in Cancer Cells:
Mechanisms and Therapeutic Approaches
296
297
297
298
300
301
303
304
305
308
309
310
311
311
334
337
339
342
343
347
350
375
Chi Chun Wong and Jun Yu
11.1 Introduction
11.2 Epigenetic Alterations in Human Cancers 11.3 Metabolic Alterations in Human Cancers
375
376
379
Contents
11.4 Interplay between Epigenetics and Tumor
Metabolism
381
11.4.2 Acetyl-CoA Influences Histone Acetylation
381
11.4.1 Modulation of Epigenetics by Tumor
Metabolism 11.4.3 SAM/SAH Ratio Regulates DNA and
Histone Methylation
11.4.4 TCA Cycle Metabolites Modulate DNA
and Histone Demethylation 11.4.5 Succinate and Fumarate drive
DNA/Histone Methylation
11.4.6 2-Hydroxylglutarate in IDH1/IDH2
Mutant Cancers Drive DNA/Histone
Methylation
11.5 Therapeutic Approaches
11.5.1 Inhibition of Acetyl-CoA Production
Using Glycolysis Inhibitors
11.5.2 Inhibition of Succinate/Fumarate/2 Hydroxylglutarate Using Glutaminolysis
Inhibitors 11.5.3 Inhibition of 2-Hydroxylglutarate Using
IDH1/2 Inhibitors 11.5.4 Inhibition of One Carbon Metabolism
by Limiting Methionine Cycle 11.5.5 Inhibition of DNA Methylation by
DNMTs
11.5.6 Inhibition of Tumor Metabolism by
HDACi
11.6 Conclusion
Index
381
383
385
385
387
389
389
390
390
391
392
393
393
403
xiii
Preface The relations between biocatalysis and pharmaceutical sciences are manifold. Outstanding aspects are the excellent properties of biocatalysts which are among others their high chemo-, regio-, and enantioselectivities, making them particularly suitable for the synthesis of safe chiral drug intermediates and drugs. Furthermore, several (engineered) enzymes find increasing application for the treatment of important and in part serious diseases, such as fibrinolytic disorders, cancer, or the rare lysosomal storages diseases. Drug discovery also comprises the isolation of therapeutic enzymes and drugs from natural sources such as microorganisms and plants; the blockbuster anticancer drug paclitaxel is an early example (see this volume, Chapter 2). Finally enzymes and microorganisms are indispensable in connection with the degradation of pharmaceuticals, including antibiotics that entered the ecosystem with potentially hazardous consequences. These issues are discussed in volumes 4 to 7 of this Series on Biocatalysis. The present volume 7 focuses on drugs, inherited diseases, and epigenetics. In addition, several chapters are devoted to natural sources of drugs, as well as to their degradation, and to drug resistance mechanisms. Many enzymes involved in different biocatalytic processes require vitamin B6 as cofactor. The first chapter, written by Jonathan Rosenberg, Björn Richts, and Fabian M. Commichau, summarizes recent findings concerning biosynthesis and homeostasis of vitamin B6 metabolism with a focus on prokaryotic microorganisms. Procedures for developing microbial fermentation processes with the aim to produce vitamin B6, novel routes for vitamin B6 biosynthesis and their potential for overproducing the commercially valuable substance, as well as bottlenecks of the vitamin B6 biosynthetic pathways together with strategies to overcome existing limitations are also described. “Exploring alternative Taxol sources: Biocatalysis of 7-β-xylosyl10-deacetyltaxol and application for Taxol production” is the title of Chapter 2, authored by Wan-Cang Liu, Bing-Juan Li, Ting
xvi
Preface
Gong, and Ping Zhu. Taxol is a very successful anticancer drug, and the long-term supply of Taxol is a critical issue due to the fact that it accumulates only in very low concentrations in the natural source of the drug, the bark of yew trees; however, Taxol analogues occur in much higher concentrations. The authors developed a one-pot reaction system for the bioconversion of the analogue 7-β-xylosyl-10-deacetyltaxol isolated from dried stem bark to Taxol. Using fed-batch high-cell-density fermentation and microbial biocatalysis, they achieved a yield of over 600 mg/mL Taxol. Many drugs are of plant origin. In addition, molecular farming through plant engineering is a cost-effective possibility to produce therapeutic and prophylactic proteins. Prakash Narayana Reddy, Krupanidhi Srirama, and Vijaya R. Dirisala comment on this topic in Chapter 3 and explain why plants are ideal for producing safer and effective biobetters due to the possibility of producing therapeutics such as vaccines, antimicrobial peptides or antibodies with specific and mammalian glycoforms using glyco-engineered plant hosts, which is presently not possible by existing conventional cell culture systems. They also address existing public concerns regarding the use of genetically modified organism for generating plant-made pharmaceuticals. A variety of pharmaceuticals, including so-called blockbusters such as fluoxetine, sofosbuvir, and atorvastatin, contain fluorine. The importance of this group of drugs can be derived from the fact that in 2017, 8 out of the 29 small molecules approved by the U.S. Food and Drug Administration contained this element. Cormac D. Murphy and Aoife Phelan discuss the production of fluorinated antibiotics in microorganisms, the biological production of [18F] labeled compounds for positron emission tomography analysis, the employment of microorganisms for fluorinated drug design, and the production of fluorinated drug metabolites in microorganisms. They close their informative contribution with a summary of biodegradation studies on fluorinated drugs. Chapter 5, about successful screening of potent microorganisms producing L-asparaginase, has been provided by Archana Vimal and Awanish Kumar. The enzyme has therapeutic application among others in the treatment of varies types of cancer and finds also application as the biological component in biosensors for determining the l-asparagine content in the blood samples of
Preface
leukemia patients. The aspects discussed here include different methods of screening potential sources (bacterial, fungal, animal, etc.) for this protein, the description of a variety of assay-based approaches, activators, and inhibitors of the enzyme, and finally the pharmaceutical application of l-asparaginase. The topic “biotransformation of xenobiotics in living systems”— most drugs are xenobiotics—has been treated by Maja Đanić and Momir Mikov. The authors first discuss biotransformations of xenobiotics/drugs catalyzed in the presence of hepatic enzymes, a process divided into phase I (activation by oxidations, reductions and hydrolysis) and phase II metabolism (conjugation of the activated xenobiotics with an endogenous substrate catalyzed by transferases). In addition, emphasis is put on metabolism at the intestinal level, in particular on the role of the gut microflora in xenobiotic biotransformation. The authors underline the importance of studying the gut microbiome contribution to drug pharmacokinetics as an integral part of drug development processes. This is followed by Chapter 7, where Muhammad B. Asif and Faisal I. Hai tackle the problem that a high amount of pharmaceutically active compounds and their intermediates find their way into different environmental systems through municipal and hospital wastewater, pharmaceutical industry effluents and other sources. The authors describe in detail the state of the art of processes (whole-cell WRF and/or enzyme-based treatment systems) where white-rot fungi (WRF), using their intracellular or extracellular ligninolytic enzymes (laccase, lignin peroxidase, manganese peroxidase, and versatile peroxidase) are employed to degrade recalcitrant compounds in waste water including drugs. Special attention is given to the influence of structural properties of the drugs to be degraded and the impact of the physicochemical characteristics of the wastewater on drug removal. The subsequent chapter, written by Thomas Hahn, Fabian Haitz, Jan Gajewski, Marius Mohr, Marc Beckett, and Susanne Zibek, also deals with the environmental problems caused by pharmaceutical pollutions of municipal sewage. Apart from political and societal aspects, the chapter provides an overview of the elimination of pharmaceuticals via physical and chemical methods (use of activated carbon, ozonation, and combination of both) which are then compared with the removal of pharmaceutical pollutions from municipal sewage
xvii
xviii
Preface
mediated by laccases. In addition, the structural and kinetic properties of laccases, strategies for their immobilization (e.g., the immobilization of laccase on activated carbon), and the different laccase-mediator-systems with their pro and cons are described in detail. The World Health Organization (WHO) recently stated that “antibiotic resistance is one of the biggest threats to global health, food security, and development today.” In a contribution authored by Ana Leticia Gori Lusa, Felipe Wakasuqui, Christian Betzel, and Carsten Wrenger, this issue has been taken up with the example of the mechanism of drug resistance in Staphylococcus aureus and its importance for future drug discovery and development. Drugs used to treat Staphylococcus aureus infections are reviewed, together with strategies developed by bacteria to repel their action. The need to discover new drugs involves the use of high-resolution methods to select a target molecule and to identify lead compounds that are successively optimized among others via structural investigations into complexes formed with proteins. The next chapter is about genome editing with engineered nucleases and gene therapies. It contains sections introducing the fundamentals of the genome editing techniques (zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced, short palindromic repeat (CRISPR) technologies), therapeutic genome editing, including different delivery techniques, genome editing and disease models, and induced pluripotent stem cells. Additional aspects treated are genome editing studies in non-clinical development and clinical trials, examples of non-clinical developments (infectious, monogenic, neurodegenerative diseases, CAR-T cell therapy and CRISPR), genome editing-based therapeutics in clinical trials and off-target effects. Recent advances in the field of gene therapy are reviewed. Finally, the commercialization of genome editing, together with ethical concerns and regulatory aspects, is discussed. Epigenetics is the science of heritable changes in gene expression that cannot be traced back to changes in the underlying DNA sequence, and disruptions of epigenetic processes are associated with initiation and progression of cancer. This is the topic of the final chapter authored by Chi Chun Wong and Jun Yu,
Preface
which deals with epigenetic and metabolic alterations in human cancer cells and the interplay between epigenetics and tumor metabolism resulting in epigenetic dysfunction. The authors explain how drugs targeting tumor metabolism can be combined with epigenetic drugs to achieve a synergistic effect in tumor inhibition. Examples of therapeutic approaches are given aiming among others at reversing aberrant histone acetylation and DNA/ histone methylation—both well-established cancer characteristics. The authors emphasize the importance of considering the whole tumor microenvironment, including stromal cells, T-cells, macrophages, and other immune cell types, for developing novel metabolic and epigenetic drugs. This volume of the Jenny Stanford Series on Biocatalysis provides an insight into a variety of important aspects of pharmaceutical biocatalysis beyond the synthesis and application of active pharmaceutical ingredients. These include natural sources of drugs, drug metabolism in the human body, environmental problems caused by their use and possibilities to mitigate them, and the threatening phenomenon “antibiotic resistance.” The information is completed by actual articles about genome editing approaches and the relationship between epigenetics and human cancers. Peter Grunwald
xix
Chapter 1
Fermentative Production of Vitamin B6 Jonathan Rosenberg,a Björn Richts,a and Fabian M. Commichaub aDepartment of General Microbiology, Georg-August-University Goettingen,
Grisebachstr. 8, D-37077 Göttingen, Germany
bBTU Cottbus-Senftenberg, Institut für Biotechnologie, FG Synthetische Mikrobiologie,
Universitätsplatz 1, 01968 Senftenberg, Germany
[email protected]
1.1 Introduction Vitamin B6 has been discovered almost one century ago and is an essential organic micronutrient for organisms from all kingdoms of life (György, 1956; Hellmann and Mooney, 2010; Kraemer et al., 2012; Eggersdorfer et al., 2012). Vitamin B6 collectively designates the water-soluble vitamers pyridoxal (PL), pyridoxine (PN), and pyridoxamine (PM), and their respective phosphate esters pyridoxal 5-phosphate (PLP), pyridoxine 5-phosphate (PNP), and pyridoxamine 5-phosphate (PMP) (Fig. 1.1A; Rosenberg, 2012; Rosenberg et al., 2017). PLP is the most important vitamer serving as a cofactor for a plethora of proteins and enzymes (Mehta et al., 1993; Jansonius, 1998; Mehta and Christen, 2000; Christen and
Pharmaceutical Biocatalysis: Drugs, Genetic Diseases, and Epigenetics Edited by Peter Grunwald
Copyright © 2021 Jenny Stanford Publishing Pte. Ltd.
ISBN 978-981-4877-14-5 (Hardcover), 978-1-003-04541-0 (eBook)
www.jennystanford.com
2
Fermentative Production of Vitamin B6
Mehta, 2001; Eliot and Kirsch, 2004; Phillips, 2015). Estimations revealed that over 160 enzymes with distinct catalytic activities require vitamin B6 as a cofactor (about 4% of all described catalytic activities) (Percudani and Peracchi, 2009). Most of the PLP-dependent enzymes are involved in biosynthesis of amino acids, decarboxylation and racemization reactions, cleavage of Cα-Cβ bonds, α-, β- and γ-elimination or replacement reactions (John, 1995; Mehta and Christen, 2000; Christen and Mehta, 2001; Eliot and Kirsch, 2004). Moreover, PMP serves as a cofactor for enzymes of deoxysugar biosynthetic pathways (Burns et al., 1996; Romo and Liu, 2011). Furthermore, PLP modulates the activity of DNA-binding transcription factors in eukaryotes and prokaryotes (Oka et al., 2001; Huq et al., 2007; El Qaidi et al., 2013; Belitsky, 2004a; Belitsky, 2014; Tramonti et al., 2015, 2017 2018; Suvorova and Rodionov, 2016; Tramonti et al., 2017). The finding that about 1.5% of the genes of many free-living prokaryotes code for PLP-dependent proteins underlines the importance of the B6 vitamer for the function of proteins and catalytic enzymes (Percudani and Peracchi, 2003). There is also evidence that vitamin B6 is implicated in oxidative stress responses in plants (Bilski et al., 2000; Mooney and Hellmann, 2010; Moccand et al., 2014; Vanderschuren et al., 2013). Thus, vitamin B6 fulfils a variety of vital functions in different cellular processes (Fitzpatrick et al., 2007; Mooney et al., 2009; Vanderschuren et al., 2013; Parra et al., 2018). Animals and humans have to ingest vitamin B6 with their diet because these organisms are unable to synthesize the micronutrient (Fitzpatrick et al., 2007, 2010; Kraemer et al., 2012). Vitamin B6 limitation has been associated with neurological disorders such as epileptic encephalopathy due to inherited errors in the enzymes interconverting B6 vitamers in the socalled “salvage pathway” (Mills et al., 2005; Bagci et al., 2008; di Salvo et al., 2012). Vitamin B6 deficiency can also be caused by interactions between drugs, such as contraceptives, and enzymes of the salvage pathway (Lumeng et al., 1974; Lussana et al., 2003; di Salvo et al., 2011). Therefore, vitamin B6 is of commercial interest for improving the quality of the food and for applications in the pharmaceutical industry (Rosenberg et al., 2017; AcevedoRocha et al., 2019). In the food industry, the hydrochloride salt of
Introduction
the B6 vitamer PN is usually used in combination with other vitamins in a variety of food products (Domke et al., 2005; Eggersdorfer et al., 2012). Vitamin B6 is also added to the food that is used for intensive animal farming to improve animal health and to enhance the yield (Johnson et al., 1950; Verbeek, 1975; Eggersdorfer et al., 2012). Many studies report positive effects of vitamin B6 although a large number of commercial products contain this compound. Only a few studies revealed that vitamin B6 can be toxic. A recent case described photosensitive skin darkening, hyperemesis and diarrhea as toxic effects, which disappeared soon after intoxication stopped (Cupa et al., 2015). Moreover, long-time supplementation of PN in higher doses is known to cause sensory neuropathy (Schaumburg et al., 1983; Albin et al., 1987). This effect is also used as a model for neuropathy (Hong et al., 2009; Potter et al., 2014). So far the B6 vitamers are fully chemically synthesized via five different routes with variations, partly using expensive and/or toxic chemicals such as hydrogen cyanide, phosphorous pentoxide, and 1,4-butenediol (Pauling and Weimann, 1996; Kleemann et al., 2008; Eggersdorfer et al., 2012; Acevedo-Rocha et al., 2019). Several extensive attempts have been made by the biotech industry and academia to engineer microorganisms for vitamin B6 production by classical mutagenesis and by genetic modification (Pflug and Lingens, 1978; Ischikawa et al., 1997; Yocum et al., 2004; Hoshino et al., 2006a,b,c; Commichau et al., 2014, 2015; Rosenberg et al., 2017; Acevedo-Rocha et al., 2019). Unfortunately, none of the attempts were promising enough to establish an effective fermentation process (Rosenberg et al., 2017; Acevedo-Rocha et al., 2019). However, there is still considerable interest on the industrial side to shift from chemical synthesis processes to environmentally sustainable fermentation technologies (Acevedo-Rocha et al., 2019). This chapter summarizes recent findings regarding biosynthesis and homeostasis of vitamin B6 metabolism with a focus on prokaryotic microorganisms (bacteria). We also describe the approaches for developing microbial fermentation processes to produce vitamin B6 using microorganisms. Furthermore, we describe novel routes for vitamin B6 biosynthesis that have been discovered recently and discuss their potential for overproducing
3
4
Fermentative Production of Vitamin B6
the commercially valuable substance. Finally, we highlight bottlenecks of the vitamin B6 biosynthetic pathways and propose strategies that might help to circumvent these limitations to improve vitamin B6 production.
1.2 De novo Synthesis of Vitamin B6
Two non-homologous pathways for de novo vitamin B6 biosynthesis are known (Fig. 1.1B; Mittenhuber, 2001; Tanaka et al., 2005; Fitzpatrick et al., 2007, 2010; Rosenberg et al., 2017; Parras et al., 2018). The longer vitamin B6 biosynthetic pathway that was first discovered in the Gram-negative model bacterium Escherichia coli depends on the sugar deoxyxylulose 5-phosphate (DXP). The DXP-dependent pathway consists of two branches and seven enzymatic steps. In the longer branch of this pathway, the erythrose 4-phosphate (E4P) dehydrogenase (Epd), the 4-phosphoerythronate (4PE) dehydrogenase (PdxB and PdxR in E. coli and in the Gram-negative bacterium Sinorhizobium meliloti, respectively), and the 3-phosphoserine aminotransferase (SerC) convert E4P, which is derived from the pentose phosphate pathway, to 4-phosphohydroxy-L-threonine (4HTP) (Fig. 1.1B; Zhao et al., 1995; Drewke et al., 1996; Yang et al., 1998; Tazoe et al., 2006; Rudolph et al., 2010). 4HTP is then oxidized by the 4HTP dehydrogenase (PdxA) to 2-amino-3-oxo-4 phosphohydroxy)butyric acid that spontaneously decarboxylates to 3-phosphohydroxy-1-aminoacetone (PHA) (Cane et al., 1998; Laber et al., 1999; Banks and Cane, 2004). The PNP synthase PdxJ produces the B6 vitamer PNP from PHA and DXP, of which the latter substrate is generated by the DXP synthase Dxs from glyceraldehyde 3-phosphate (G3P) and pyruvate in the short branch of the DXP-dependent vitamin B6 pathway (Cane et al., 1999; Laber et al., 1999). The final step is catalyzed by the PNP oxidase PdxH and yields in the biologically active B6 vitamer PLP (Fig. 1.1B; di Salvo et al., 1998, 2002, 2003). The DXPdependent vitamin B6 pathway has been intensively studied in E. coli. However, an in silico analysis revealed that it is only present in α- and γ-proteobacteria, who acquired it with the function of PdxB after the DXP-independent vitamin B6
De novo Synthesis of Vitamin B6
pathway had been lost in their ancestral lineage (Mittenhuber, 2001; Tanaka et al., 2005; Rosenberg et al., 2017). Additionally, the pathway was constituted by members of the α-proteobacteria who acquired pdxR, which is not homologous to pdxB, but fulϐils the same enzymatic function (Tazoe et al., 2006). It is also interesting to note that two enzymes of the DXP-dependent vitamin B6 route are involved in other metabolic pathways. SerC is essential for de novo biosynthesis of serine and the Dxs provides DXP as a precursor for thiamine and isoprenoids to the cell (Dempsey and Itoh, 1970; Sprenger et al., 1997).
Figure 1.1 (A) The B6 vitamers pyridoxal (PL), pyridoxal 5-phosphate (PLP), pyridoxine (PN), pyridoxine 5-phosphate (PNP), pyridoxamine (PM), and pyridoxamine 5-phosphate (PMP). PLP is the physiologically most-relevant B6 vitamer. (B) The deoxyxylulose 5-phosphate (DXP)dependent and DXP-independent vitamin B6 biosynthetic routes and the salvage pathway for the interconversion of the B6 vitamers. Epd, erythrose 4-phosphate dehydrogenase; PdxB (PdxR), 4-phosphoerythronate dehydrogenase; SerC, 3-phosphoserine aminotransferase; PdxA, 4phosphohydroxy-L-threonine dehydrogenase; PdxJ, PNP synthase; Dxs, 1-deoxyxylulose 5-phosphate synthase; PdxH, PNP oxidase; PdxS (PLP synthase subunit) and PdxT (glutaminase subunit) form the PLP synthase complex; PdxK, PL kinase present in B. subtilis and E. coli; PdxY, PL kinase present in E. coli. PdxK from B. subtilis has PN, PL, and PM kinase activity (Park et al., 2004).
5
6
Fermentative Production of Vitamin B6
The DXP-independent vitamin B6 biosynthetic pathway is much shorter because it involves only the PdxST enzyme complex, consisting of 12 PdxS and 12 PdxT subunits (Ehrenshaft and Daub, 2001; Belitsky, 2004b; Burns et al., 2005; Raschle et al., 2005; Strohmeier et al., 2006). PdxT is a glutaminase that converts glutamine to glutamate and ammonium, of which the latter serves as a substrate for the PLP synthase PdxS (Belitsky, 2004b). PdxS catalyses the reaction from ribulose 5-phosphate (Ru5P) and G3P to PLP. Due to triose and pentose isomerase activity, it can use either Ru5P or ribose 5-phosphate (Ri5P) together with either G3P or dihydroxyacetone phosphate (DHAP). Thus, the PdxS enzyme complex unifies three enzymatic activities: triose isomerase and pentose isomerase activity as well as imine formation activity for PLP synthesis (Burns et al., 2005). Even though the DXPindependent vitamin B6 pathway has been discovered a few years ago, it is more abundant in nature than the DXP-dependent route. It is present in archaea, bacteria, fungi, plants, and Plasmodium and in the sponge Suberites domuncula (Seack et al., 2001; Ehrenshaft and Daub, 2001; Fitzpatrick et al., 2007; Guédez et al., 2012; Rosenberg et al., 2017). Moreover, the DXP-independent vitamin B6 pathway emerged earlier and it has been lost several times in the course of evolution (Tanaka et al., 2005). Those organisms that are capable of producing vitamin B6 use either the DXP-independent of the DXP-dependent pathway. However, many organisms that synthesize vitamin B6 or need to ingest it possess a salvage pathway for the interconversion of the B6 vitamers (Fig. 1.1B; Fitzpatrick et al., 2007). For instance, E. coli and the Gram-positive model bacterium Bacillus subtilis synthesize the B6-vitamer kinase PdxK that phosphorylates PN, PM and PL (Dempsey and Pachler, 1966; Yang et al., 1996, 1998; White and Dempsey, 1970; di Salvo et al., 2004; Park et al., 2004). All those organisms carrying only the salvage pathway have to take up the vitamers from the environment. So far, only two vitamin B6 transporters have been in described in eukaryotes: Tpn1p in the fungus Saccharomyces cerevisiae, and PUP1 in Arabidopsis (Stolz and Vielreich, 2003; Szydlowski et al., 2013). The Tpn1p transporters are conserved in humans as well (Hediger et al., 2013). Surprisingly, even though the auxotrophy of bacteria for vitamin B6 can be relieved by supplementation
Control of Vitamin B6 Homeostasis
with non-phosphorylated B6 vitamers, the uptake systems are unknown in bacteria.
1.3 Control of Vitamin B6 Homeostasis
The two pathways for the biosynthesis of vitamin B6 and the salvage pathway have been intensively genetically studied (Rosenberg et al., 2017). Moreover, many of the involved enzymes have been biochemically and structurally studied in the past years (Mukherjee et al., 2011; Rosenberg et al., 2017). Unfortunately, little is known about the control of biosynthesis, recycling and degradation of vitamin B6. However, detailed knowledge about the control of vitamin B6 metabolism is required to facilitate the metabolic engineering of microorganisms for vitamin B6 overproduction. It is also poorly understood how PLP is delivered to the target proteins that require the vitamin for function. However, vitamin B6 biosynthesis has to be controlled because PLP is highly reactive and intermediates of the DXP-dependent pathway are toxic (Shames et al., 1984; Drewke et al., 1993; Farrington et al., 1993; Mizushina et al., 2003; Vermeersch et al., 2004; Commichau et al., 2015). For instance, PLP inhibits enzymes that are involved in DNA metabolism and in central metabolism in eukaryotes (Mizushina et al., 2003; Vermeersch et al., 2004; Lee et al., 2005). For E. coli it has been shown that the addition of vitamin B6 affects multiple metabolic pathways that are involved in amino acid biosynthesis (Vega and Margolin, 2017; Sugimoto et al., 2017). Thus, excess of vitamin B6 can negatively affect different cellular processes. The B6 vitamers PLP and PMP belong to the members of the 30 most damage-prone metabolites (Lerma-Ortiz et al., 2016). PLP is also prone to damage due to side reactions that are catalyzed by promiscuous enzymes or due to spontaneous chemical reaction (Linster et al., 2013). However, PLP is required for growth in only little amounts (Hartl et al., 2017). Therefore, PLP can be synthesized at a minimal necessary rate (Hartl et al., 2017). Probably, the perturbation of essential cellular processes is prevented by the low requirement of PLP and its low cellular concentration. However, PLP metabolism seems to be regulated in some organisms. In E. coli, a positive correlation between the expression of the pdxB and pdxA genes
7
8
Fermentative Production of Vitamin B6
and the growth rate has been reported (Pease et al., 2002). Probably, the amount of PdxB and PdxA enzymes has to be increased to meet the demand of vitamin B6 needed to achieve high growth rates, possibly due to its involvement in amino acid and thus protein biosynthesis. However, the molecular mechanism behind the growth rate-dependent regulation is still unknown. Recently, it has been demonstrated that vitamin B6 biosynthesis is positively controlled by the DNA-binding transcription factor PdxR (not to be confused with the PdxR enzyme from S. meliloti), which belongs to the MocR subfamily of transcriptional regulators. This regulation was shown for the Gram-positive bacteria Bacillus clausii, Corynebacterium glutamicum, Listeria monocytogenes, and Streptococcus mutans (Bramucci et al., 2011; Jochmann et al., 2011; Belitsky, 2014; Liao et al., 2014; Tramonti et al., 2015, 2017, 2018; Suvorova and Rodionov, 2016). At low PLP levels PdxR activates the expression of the divergently transcribed pdxST genes encoding the PLP synthase complex. By contrast, at increased PLP levels, the B6 vitamer acts as an inhibitor of the transcription factor PdxR, which then prevents its own synthesis (Belitsky, 2014). It remains to be elucidated whether de novo synthesis of PLP is controlled in other organisms lacking a homolog of the transcription factor PdxR. An excess of vitamin B6 might also be prevented by dephosphorylation and export. It has been shown that the S. meliloti strain IFO14782 possesses the phosphatase PdxP, which can dephosphorylates PNP and PLP (Tazoe et al., 2005; Nagahashi et al., 2008). Recently, the PLP phosphatase YbhA has been identified in E. coli (Saito et al., 2006; Sugimoto et al., 2017). The enzyme also displays in vitro phosphotransferase and phosphatase activity towards different sugars and sugar phosphates like fructose 1,6bisphosphate (Saito et al., 2006; Kuznetsova et al., 2006). However, the dephosphorylation of fructose 1,6-bisphosphate by YbhA does not seem to be physiologically relevant (Sugimoto et al., 2017). YbhA shows about 31% overall sequence identity with YitU from B. subtilis. YitU is a HAD phosphatase that has a minor activity in dephosphorylating the riboflavin precursor 5-amino6-ribiylamino-2,4(1H,3H)-pyrimidinedione 5-phosphate (Sarge et al., 2015). It will be interesting to evaluate whether the protein may act as a PNP/PLP phosphatase in B. subtilis. The transporter involved in the export of B6 vitamers also remains to be
Control of Vitamin B6 Homeostasis
identified. However, the PNP/PLP phosphatases together with the export system could be major players in controlling the intracellular vitamin B6 levels. Therefore, experiments targeting these important aspects of B6 homeostasis have to be pursued. Genetic screenings for PL-resistant mutants might reveal PL importers, while random mutagenesis approaches with selection for more PL-susceptible strains could shed light on export systems. Control of vitamin B6 homeostasis might also be achieved at the level of enzyme activity (di Salvo et al., 2011). For instance, the PNP oxidase PdxH and PN/PM/PL kinase PdxK from E. coli are regulated by PLP (White and Dempsey, 1970; Zhao and Winkler, 1995; Yang et al., 1996; Yang and Schirch, 2000; Fu et al., 2001; Ghatge et al., 2012). The B6 vitamers PL and PLP tightly bind to the lysine residue at the position 229 of PdxK, which inhibits the kinase (Ghatge et al., 2012; di Salvo et al., 2015). PLP also binds to a non-catalytic site of PdxH (Yang and Schirch, 2000). The PdxK-PLP and PdxH-PLP complexes could act as chaperones transferring the cofactor to PLP-requiring enzymes (Yang and Schirch, 2000; Ghatge et al., 2012). Indeed, PdxK specifically interacts with metabolic enzymes and the kinase can partially be recovered from the PdxK-PLP complex by transferring the PLP to an apo-B6 enzyme (Cheung et al., 2003; Ghatge et al., 2012). Similarly, the B. subtilis aspartate aminotransferase triggers hydrolysis and release of PLP from the PdxST enzyme complex, thus allowing the transfer of the highly reactive cofactor to a vitamin B6-dependent protein (Moccand et al., 2011). Similar to the E. coli biotin protein ligase, which is extraordinarily specific and attaches the cofactor to few proteins, the PLP-synthesizing enzymes might assure that the cofactor PLP is only attached to target proteins (Choi-Rhee et al., 2004). Alternatively, PLP bound to cellular amino acids could be the mechanism that directs the vitamin to the apo-enzymes (di Salvo et al., 2011). It remains to be elucidated whether the PdxHand PdxK-dependent or the amino acid-dependent transfer of vitamin B6 to the target proteins is physiologically relevant. Recently, it has been shown that YggS from E. coli is a PLPbinding protein, which belongs to a highly conserved protein family and exists in almost all kingdoms of life, including bacteria, fungi and animals (Ito et al., 2013). YggS shows about 33% overall sequence identity with YlmE protein of unknown
9
10
Fermentative Production of Vitamin B6
function from B. subtilis (Zhu and Stülke, 2017). The high conservation of this protein indicates that it must fulfill an important cellular function. Indeed, the lack of YggS in E. coli results in imbalance of PLP homeostasis, sensitivity towards PN and perturbation of biosynthesis of branched-chain amino acids (Prunetti et al., 2016). YggS might serve as a carrier that delivers PLP to apo-B6 proteins or fulfils a protective function in preventing inactivation of essential proteins by the modification of lysine residues. Recently, it has been reported that the YggS homolog from Streptomyces coelicolor plays a role in sporulation specific cell division (Zhang et al., 2018). However, the precise function of this important and abundant protein in controlling vitamin B6 homeostasis and other cellular processes remains to be determined. Finally, PLP homeostasis could be achieved by its degradation. Several years ago it was reported that bacteria like Mesorhizobium loti, Acetobacter rancens and some pseudomonads degrade vitamin B6 and use it as a carbon and nitrogen source for growth (Rodwell et al., 1958; Yoshikane et al., 2006; Mukherjee et al., 2011). As yet, two vitamin B6 degradation pathways have been described but the involved genes were only identified in the M. loti strain MAFF303099 (Mukherjee et al., 2011). Certainly, other pathways for the degradation of vitamin B6 will be identified in the future.
1.4 Engineering Microorganisms for the
Production of B6 Vitamers
Early attempts for the overproduction of vitamin B6 were performed with wild-type isolates of bacteria and fungi in the genera: Achromobacter, Bacillus, Flavobacterium, Klebsiella, Vibrio, and Kluveromyces, Pichia, and Simuliomyces, respectively (Table 1.1). Previously, a maximum of about 25 mg/L of B6 vitamers were obtained using the yeast Pichia guilliermondii NK-2 without genetic modification of the organism (Nishio et al., 1973). The first strain engineering approach for vitamin B6 production was reported about 15 years ago. The introduction and overexpression of the B. subtilis pdxST genes in E. coli resulted in the production of more than 60 mg/L of B6 vitamers within 48 h of cultivation (Yocum et al., 2004). The vitamin B6 production was further
Engineering Microorganisms for the Production of B6 Vitamers
enhanced to 78 mg/L within 31 h of cultivation by overexpressing the native epd, pdxJ, and dxs genes in E. coli (Hoshino et al., 2006a). The same group demonstrated that the S. meliloti strain IFO14782, a natural overproducer of vitamin B6, produces about 100 mg/L B6 vitamers within 168 h (Hoshino et al., 2006b). The overexpression of the native dxs gene and the E. coli epd gene in the S. meliloti strain increased the production of vitamin B6 to 1.3 g/L (Table 1.1; Hoshino et al., 2006b). Also B. subtilis, a bacterium that is widely used for industrial applications (Schallmey et al., 2004; van Tilburg et al., 2019), has been genetically engineered for vitamin B6 production using a heterologous DXP-dependent vitamin B6 pathway (AcevedoRocha et al., 2019). In a first attempt, the E. coli epd gene and the pdxR, serC, pdxA, and pdxJ genes from the S. meliloti strain IFO14782 strain were codon-optimized, assembled to artificial operons whose expression is driven by constitutively active promoters, and introduced in single copy into the B. subtilis chromosome (Commichau et al., 2014). The heterologous pathway was shown to be fully functional and the engineered bacteria produced about 41 mg/L PN within 72 h of incubation (Table 1.1). Unfortunately, the B. subtilis strain containing the non-native DXP-dependent vitamin B6 pathway was genetically unstable, which might be due to unbalanced expression of the enzymes of the heterologous pathway and accumulation of toxic intermediates (Commichau et al., 2014). A comparison of the kinetic properties of the enzymes of the DXP-dependent pathway shows that PdxA and PdxJ are catalytically inefficient enzymes (Table 1.2). Moreover, a quantitative proteomics analysis revealed that both enzymes were not very abundant in the engineered B. subtilis strain (Commichau et al., 2014). Unfortunately, the enzymes are required in high amounts to synthesize PNP from 4HTP, an intermediate that had been shown to be highly toxic for bacteria because it inhibits threonine and isoleucine biosynthesis (Shames et al., 1984; Drewke et al., 1993; Farrington et al., 1993; Kim et al., 2010; Commichau et al., 2014, 2015). Thus, the overexpression of the highly active Epd enzyme (Table 1.2), which together with the PdxR enzyme and SerC, generates 4HTP might be the reason for a strong selective pressure acting against the heterologous vitamin B6 pathway (Fig. 1.1B; Commichau et al., 2014).
11
pdxST-Bs
Escherichia coli
Pichia guilliermondii isolate NK-2
—
Flavobacterium
isolate
isolate
Vibrio sp. M31
Flavobacterium sp. 238-7
Mut
—
—
Bacillus subtilis
Achromobacter cycloclastes
Saccharomyces microsporus
—
—
Klebsiella sp.
Kluyveromyces marxianus
Genotypea
Enzyme
PL
Vitamin B6
Vitamin B6
Vitamin B6
Vitamin B6
Vitamin B6
Vitamin B6
Vitamin B6
Vitamerb
MM + yeast extract
Vitamin B6
MM + Hydrocarbon, Vitamin B6 yeast extract, Tween80
MM + CAA
Peptone, Glycerol, salts, Mn
Peptone, Glycerol, salts
MM
MM + CAA
MM
MM
MM + CAA
Medium
Table 1.1 Vitamin B6 production by natural isolates and engineered bacteria
>60
25
4
18
5
2–5
3–4
3
2
2
Titer [mg/L]
48
144–216
60
70
100
96
36–42
168
96
60
Time [h]
Yocum et al., 2004
Nishio et al., 1973
Suzue and Haruna, 1970
Tani et al., 1972
Tani et al., 1972
Pflug and Lingens, 1978
Ishida and Shimura, 1970
Scherr and Rafaelson, 1962
Pardini and Argoudelis, 1968
Suzue and Haruna, 1970
Reference
12 Fermentative Production of Vitamin B6
MM + yeast extract epd-Ec, pdxR-, serC-, pdxA-, pdxJSm
pdxA-Ec, pdxJ-Sm MM + amino acid cocktail + 4HT
Bacillus subtilis
Bacillus subtilis
MM + yeast extract
PN
PN
PN
PN
PN
PN
Vitamin B6
Vitamerb
65
41
1300
362
149
103
>78
Titer [mg/L]
72
72
168
168
216
168
31
Time [h]
Commichau et al., 2015
Commichau et al., 2014
Hoshino et al., 2006b
Hoshino et al., 2006c
Nagahashi et al., 2008
Hoshino et al., 2006b
Hoshino et al., 2006a
Reference
B6” refers to a mixture of vitamers (see Fig. 1.1A).
Bacillus subtilis; Ec, Escherichia coli; Sm, Sinorhizobium meliloti; Mut, classical mutagenesis; MM, minimal medium.
b“Vitamin
aBs,
epd-Ec, pdxJ-Sm
Sinorhizobium meliloti IFO14782
MM + yeast extract
Mut, pdxJ-Sm
Sinorhizobium meliloti IFO14782
MM + yeast extract
MM + yeast extract
pdxP-Sm, pdxJ-Ec
—
Sinorhizobium meliloti IFO14782
Sinorhizobium meliloti IFO14782
epd-, pdxJ-, dxs-Ec MM + yeast extract
Escherichia coli
Medium
Genotypea
Enzyme
Engineering Microorganisms for the Production of B6 Vitamers 13
OHPB, Glutamate
4HTP
DXP, PHA
Pyruvate, G3P
Escherichia coli
Escherichia coli
Escherichia coli
PdxA
PdxJ
Dxs
PdxH
Escherichia coli
PNP, PMP
PE
Escherichia coli
SerC
Sinorhizobium meliloti
PE, OG
Escherichia coli
PdxB
PdxR
EP
Escherichia coli
Substrate(s)
Epd
Enzyme Organism
DXP
PLP
PNP
AHP
4HTP
OHPB
OHPB
PE
Mg2+, Mn2+, TPP
FMN
n. a.
NAD, Mg2+
PLP
FAD
NAD
NAD
n. a.
PLP (–)
n. a.
n. a.
n. a.
n. a.
n. a.
n. a.
DXP-dependent pathway
96, 240
2, 105
26.9
85
110c
n. a.
2.9
0.8
0.76, 1.72
0.07
1.66
0.15d
n. a.
1.4
510–960, 20–200 74–800
Product(s) Cofactor(s) Effectors KM [µM]a kcat [s–1]b
Table 1.2 Published kinetic properties of enzymes involved in vitamin B6 metabolism
Cane et al., 2001; Kuzuyama et al., 2000
Zhao and Winkler, 1995
Cane et al., 1999
Cane et al., 1998, 1999; Laber et al., 1999
Drewke et al., 1996
Tazoe et al., 2006
Rudolph et al., 2010
Zhao et al., 1995; Boschi-Muller et al., 1997
References
14 Fermentative Production of Vitamin B6
Mg2+, Mn2+
n. a. n. a.
n. a.
385
n. a.
n. a.
n. a.
Tazoe et al., 2005
Saito et al., 2006; Kuznetsova et al., 2006; Sugimoto et al., 2017
for the substrates/cofactors. b Assay conditions differ for the enzymes. creverse reaction was analysed. n. a., not analyzed.
PN, PL
PL
aAffinities
PdxY
Yang et al., 1998; di Salvo et al., 2004
Park et al., 2004
PNP, PLP
n. a.
0.032
White and Dempsey, 1970; di Salvo et al., 2004; Ghatge et al., 2012; di Salvo et al., 2015
Sinorhizobium meliloti
n. a.
46.6
2.34 (0.34, 0.67)
PdxP
n. a.
n. a.
100, (25, 30)
PLP
Mg2+
Mg2+
PL, PLP
0.33 × 10–3 Raschle et al., 2005
Escherichia coli
PLP
PLP
Mg2+
68, 77, 990
YbhA
PL (PN, PM), ATP
Bacillus subtilis
PdxK
PLP, (PNP, PMP)
n. a.
Salvage pathway
n. a.
PL
PL (PN, PM), ATP
Escherichia coli
PdxK
PLP
Escherichia coli
R5P, G3P, Glutamine
Bacillus subtilis
PdxST
DXP-independent pathway
Engineering Microorganisms for the Production of B6 Vitamers 15
16
Fermentative Production of Vitamin B6
Inhibitory interactions have also been observed between novel vitamin B6 metabolic routes and the native metabolic network of E. coli (Kim and Copley, 2012). Thus, the expression levels of the enzymes of a heterologous or a novel vitamin B6 pathway need to be fine-tuned to prevent the accumulation of intermediates to toxic levels. An alternative approach could be to adapt the host organisms to the heterologous pathway through continuous growth under selection for PL production. B. subtilis has also been engineered for the conversion of 4-hydroxy-L-threonine (4HT) to the B6 vitamer PN (Commichau et al., 2015). The conversion of 4HT to PN by B. subtilis required the genomic adaptation of the bacteria because like 4HTP also 4HT interferes with threonine and isoleucine biosynthesis (Westley et al., 1971; Katz et al., 1974; Drewke et al., 1993; Kim et al., 2010; Commichau et al., 2014; Rosenberg et al., 2016). The evolved B. subtilis strains had acquired mutations in (1) branched chain amino acid transporters that probably reduce uptake rate of 4HT from the medium and (2) the Phom promoter, resulting in the de-regulation of threonine biosynthesis, thus endogenous resistance to 4HT (Commichau et al., 2015; Rosenberg et al., 2016). The evolved bacteria expressing the native thrB gene, which encodes the promiscuous homoserine kinase ThrB that converts 4HT to 4HTP (Fig. 1.2), and the E. coli pdxA and S. meliloti pdxJ genes produced 65 mg/L PN from 120 mg/L 4HT (Commichau et al., 2015). Surprisingly, although 4HT was completely consumed by the engineered bacteria they did not fully convert it to PN. This observation suggests that unknown host metabolic pathways compete with the heterologous pathway for 4HT. Given the fact that the various attempts to produce industrially significant levels of B6 vitamers were unsuccessful, it is evident that we know too little about vitamin B6 function, toxicity and the regulation of its metabolism. However, there is potential for strain optimization because the improvement of a S. meliloti wild type strain producing 103 milligrams per liter within 168 h to 1.3 grams per liter could be achieved by only overproducing two genes of the B6 synthesis pathway. To overcome the hurdles and to identify the rate-limiting bottlenecks, we will need the information about the flow of metabolites into and out of the relevant synthetic pathways. This is because the production of
Novel Routes for Vitamin B6 Biosynthesis and Production
B6 in large amounts will deplete significant amounts of metabolites from glycolysis and the pentose phosphate pathway, and also cause the accumulation of toxic intermediates. Therefore, metabolic flux analysis needs to be performed as has been done for an N-acetylglucosamine producing B. subtilis strain (Liu et al., 2016).
1.5 Novel Routes for Vitamin B6 Biosynthesis and Production
Reactions in the cellular metabolic networks may occur spon taneously and independent of metabolic enzymes (Piedrafita et al., 2015). Moreover, many enzymes have promiscuous activities that are not required for the primary function of the protein and generally serve no purpose (Khersonsky and Tawfik, 2010). The promiscuous enzymes can cause a so-called “underground metabolism” and they may either act on substrates for which they evolved or on structurally related compounds (D’Ari and Casadeus, 1998; Notebaart et al., 2018). The non-enzymatic reactions as well as promiscuous enzymes are important for the evolution of metabolic pathways (Jensen, 1976; Copley, 2012; Schulenburg and Miller, 2014; Rosenberg and Commichau, 2019). About 37% of the E. coli enzymes were estimated to act on a variety of substrates and catalyze 65% of the known metabolic reactions (Nam et al., 2012). Thus, enzyme promiscuity might be an excellent starting point for the evolution of novel catalysts (Khersonsky and Tawfik, 2010; Copley, 2012). Indeed, the overexpression of native enzymes with promiscuous activities generated so-called serendipitous vitamin B6 pathways satisfy ing the PLP auxotrophy of an E. coli pdxB mutant strain (Cooper, 2010; Kim et al., 2010). Interestingly, although the serendipitous pathways divert intermediates from other metabolic pathways, they were shown to feed in into the native DXP-dependent PLP biosynthetic route (Fig. 1.2). A detailed characterization of one of the three pathways, which were identified in E. coli, revealed that the four enzymes SerA, YeaB, LtaE and ThrB connect serine to vitamin B6 biosynthesis by conversion of 3-phosphoglycerate to 4HTP through 3-phosphohydroxypyruvate, 3-hydroxypyruvate, glycolaldehyde, and 4HT. (Fig. 1.2) (Kim et al., 2010; Kim and
17
18
Fermentative Production of Vitamin B6
'" " !
/$""'$')+
%
'" ! !!
'"! !! &
' 77: